KRAS and non-small cell lung carcinoma: ,48 In the sotorasib phase 2 study, patients with KRAS G12C-mutated NSCLC who had STK11 wild type but had a KEAP1 alteration seemed to have the lowest response rate, although this was not sufficiently powered for statistical analysis.18